Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Journal of Neural Transmission (Vienna, Austria : 1996)|November 19, 2022
Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trialWolfgang Strube, Aslihan Aksar, Ingrid Bauer, et al.
Journal of Psychiatric Research|July 16, 2005
Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophreniaThomas Schneider-Axmann, Thomas Kamer, Manuel Moroni, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|February 22, 2020
Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapineElias Wagner, William G Honer, Iris E Sommer, et al.
Contemporary Clinical Trials Communications|February 20, 2020
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trialAlkomiet Hasan, Astrid Roeh, Stefan Leucht, et al.
Schizophrenia Bulletin|October 6, 2017
Predicting Response to Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia Using Structural Magnetic Resonance Imaging: A Multisite Machine Learning AnalysisNikolaos Koutsouleris, Thomas Wobrock, Birgit Guse, et al.
Schizophrenia Bulletin|August 19, 2023
Effects of Exercise on Structural and Functional Brain Patterns in Schizophrenia-Data From a Multicenter Randomized-Controlled StudyLukas Roell, Daniel Keeser, Boris Papazov, et al.
Psychological Medicine|November 18, 2024
Effects of aerobic exercise on hippocampal formation volume in people with schizophrenia - a systematic review and meta-analysis with original data from a randomized-controlled trialLukas Roell, Tim Fischer, Daniel Keeser, et al.
Psychiatry Research|September 16, 2023
Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trialIsabel Maurus, Lukas Roell, Moritz Lembeck, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
BMC Medicine|July 29, 2024
The impact of a digital guideline version on schizophrenia guideline knowledge: results from a multicenter cluster-randomized controlled trialTheresa Halms, Gabriele Gaigl, Carolin Lorenz, et al.
Pageof 11